1887

Abstract

Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that was first discovered in Kenya in 1930 and is now endemic throughout multiple African countries and the Arabian Peninsula. RVF virus primarily infects domestic livestock (sheep, goats, cattle) causing high rates of neonatal mortality and abortion, with human infection resulting in a wide variety of clinical outcomes, ranging from self-limiting febrile illness to life-threatening haemorrhagic diatheses, and miscarriage in pregnant women. Since its discovery, RVF has caused many outbreaks in Africa and the Arabian Peninsula with major impacts on human and animal health. However, options for the control of RVF outbreaks are limited by the lack of licensed human vaccines or therapeutics. For this reason, RVF is prioritized by the World Health Organization for urgent research and development of countermeasures for the prevention and control of future outbreaks. In this review, we highlight the current understanding of RVF, including its epidemiology, pathogenesis, clinical manifestations and status of vaccine development.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001296
2019-08-01
2019-08-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/100/8/1187.html?itemId=/content/journal/jgv/10.1099/jgv.0.001296&mimeType=html&fmt=ahah

References

  1. Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever. an undescribed virus disease of sheep cattle and man from East Africa. J Pathol Bacteriol 1931;34:545–579 [CrossRef]
    [Google Scholar]
  2. Daubney R, Hudson JR. Rift Valley fever. East African Medical Journal 1933;10:2–19
    [Google Scholar]
  3. Smithburn KC, Haddow AJ, Gillett JD. Rift Valley fever; isolation of the virus from wild mosquitoes. Br J Exp Pathol 1948;29:107–121
    [Google Scholar]
  4. Gear J, De Meillon B, Le Roux AF, Kofsky R, Innes RR et al. Rift Valley fever in South Africa; a study of the 1953 outbreak in the orange free state, with special reference to the vectors and possible reservoir hosts. S Afr Med J 1955;29:514–518
    [Google Scholar]
  5. Easterday BC. Rift Valley fever. Adv Vet Sci 1965;10:65–127
    [Google Scholar]
  6. Findlay GM. Rift Valley fever or enzootic hepatitis. Trans R Soc Trop Med Hyg 1932;25:229–IN11 [CrossRef]
    [Google Scholar]
  7. Dickson JL. Rift Valley fever in the Union. J S Afr Vet Assoc 1951;22:110–111
    [Google Scholar]
  8. Huang YM. A new african species of aedes (Diptera: Culicidae). Mosquito systematics 1985;17:108–120
    [Google Scholar]
  9. Linthicum KJ, Davies FG, Kairo A, Bailey CL. Rift Valley fever virus (family Bunyaviridae, genus phlebovirus). isolations from Diptera collected during an inter-epizootic period in Kenya. J Hyg 1985;95:197–209 [CrossRef]
    [Google Scholar]
  10. Lumley S, Horton DL, Hernandez-Triana LLM, Johnson N, Fooks AR et al. Rift Valley fever virus: strategies for maintenance, survival and vertical transmission in mosquitoes. J Gen Virol 2017;98:875–887 [CrossRef]
    [Google Scholar]
  11. Rostal MK, Evans AL, Sang R, Gikundi S, Wakhule L et al. Identification of potential vectors of and detection of antibodies against Rift Valley fever virus in livestock during interepizootic periods. Am J Vet Res 2010;71:522–526 [CrossRef]
    [Google Scholar]
  12. Blomström AL, Scharin I, Stenberg H, Figueiredo J, Nhambirre O et al. Seroprevalence of Rift Valley fever virus in sheep and goats in Zambézia, Mozambique. Infect Ecol Epidemiol 2016;6:31343 [CrossRef]
    [Google Scholar]
  13. Evans A, Gakuya F, Paweska JT, Rostal M, Akoolo L et al. Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife. Epidemiol Infect 2008;136:1261–1269 [CrossRef]
    [Google Scholar]
  14. Murithi RM, Munyua P, Ithondeka PM, Macharia JM, Hightower A et al. Rift Valley fever in Kenya: history of epizootics and identification of vulnerable districts. Epidemiol Infect 2011;139:372–380 [CrossRef]
    [Google Scholar]
  15. Rostal MK, Liang JE, Zimmermann D, Bengis R, Paweska J et al. Rift Valley fever: does wildlife play a role?. Ilar J 2017;58:359–370 [CrossRef]
    [Google Scholar]
  16. Anyamba A, Linthicum KJ, Small J, Britch SC, Pak E et al. Prediction, assessment of the Rift Valley fever activity in East and southern Africa 2006-2008 and possible vector control strategies. Am J Trop Med Hyg 2010;83:43–51 [CrossRef]
    [Google Scholar]
  17. Anyamba A, Chretien JP, Small J, Tucker CJ, Linthicum KJ. Developing global climate anomalies suggest potential disease risks for 2006-2007. Int J Health Geogr 2006;5:60 [CrossRef]
    [Google Scholar]
  18. Oyas H, Holmstrom L, Kemunto NP, Muturi M, Mwatondo A et al. Enhanced surveillance for Rift Valley fever in livestock during El Niño rains and threat of RVF outbreak, Kenya, 2015-2016. PLoS Negl Trop Dis 2018;12:e0006353-ee0006353 [CrossRef]
    [Google Scholar]
  19. Linthicum KJ, Britch SC, Anyamba A. Rift Valley fever: an emerging mosquito-borne disease. Annu Rev Entomol 2016;61:395–415 [CrossRef]
    [Google Scholar]
  20. Mansfield KL, Banyard AC, McElhinney L, Johnson N, Horton DL et al. Rift Valley fever virus: a review of diagnosis and vaccination, and implications for emergence in Europe. Vaccine 2015;33:5520–5531 [CrossRef]
    [Google Scholar]
  21. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 2010;41:61 [CrossRef]
    [Google Scholar]
  22. Nicholas DE, Jacobsen KH, Waters NM. Risk factors associated with human Rift Valley fever infection: systematic review and meta-analysis. Trop Med Int Health 2014;19:1420–1429 [CrossRef]
    [Google Scholar]
  23. Al-Hamdan NA, Panackal AA, Al Bassam TH, Alrabea A, Al Hazmi M et al. The risk of nosocomial transmission of Rift Valley fever. PLoS Negl Trop Dis 2015;9:e0004314 [CrossRef]
    [Google Scholar]
  24. Haneche F, Leparc-Goffart I, Simon F, Hentzien M, Martinez-Pourcher V et al. Rift Valley fever in kidney transplant recipient returning from Mali with viral RNA detected in semen up to four months from symptom onset, France, autumn 2015. Euro Surveill 2016;21: [CrossRef]
    [Google Scholar]
  25. Adam I, Karsany MS. Case report: Rift Valley fever with vertical transmission in a pregnant Sudanese woman. J Med Virol 2008;80:929 [CrossRef]
    [Google Scholar]
  26. Arishi HM, Aqeel AY, Al Hazmi MM. Vertical transmission of fatal Rift Valley fever in a newborn. Ann Trop Paediatr 2006;26:251–253 [CrossRef]
    [Google Scholar]
  27. McMillen CM, Arora N, Boyles DA, Albe JR, Kujawa MR et al. Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection. Sci Adv 2018;4:eaau9812 [CrossRef]
    [Google Scholar]
  28. Wichgers Schreur PJ, van Keulen L, Kant J, Oreshkova N, Moormann RJM et al. Co-housing of Rift Valley fever virus infected lambs with immunocompetent or immunosuppressed lambs does not result in virus transmission. Front Microbiol 2016;7:287 [CrossRef]
    [Google Scholar]
  29. Antonis AFG, Kortekaas J, Kant J, Vloet RPM, Vogel-Brink A et al. Vertical transmission of Rift Valley fever virus without detectable maternal viremia. Vector Borne Zoonotic Dis 2013;13:601–606 [CrossRef]
    [Google Scholar]
  30. McMillen CM, Hartman AL. Rift Valley fever in animals and humans: current perspectives. Antiviral Res 2018;156:29–37 [CrossRef]
    [Google Scholar]
  31. McIntosh BM, Russell D, dos Santos I, Gear JH. Rift Valley fever in humans in South Africa. S Afr Med J 1980;58:803–806
    [Google Scholar]
  32. Laughlin LW, Meegan JM, Strausbaugh LJ, Morens DM, Watten RH. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg 1979;73:630–633 [CrossRef]
    [Google Scholar]
  33. Digoutte JP, Peters CJ. General aspects of the 1987 Rift Valley fever epidemic in Mauritania. Res Virol 1989;140:27–30 [CrossRef]
    [Google Scholar]
  34. Anonymous An outbreak of Rift Valley Fever, eastern Africa, 1997-1998. EMHJ 1998;4:379–381
    [Google Scholar]
  35. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003;37:1084–1092 [CrossRef]
    [Google Scholar]
  36. Samy AM, Peterson AT, Hall M. Phylogeography of Rift Valley fever virus in Africa and the Arabian Peninsula. PLoS Negl Trop Dis 2017;11:e0005226 [CrossRef]
    [Google Scholar]
  37. Baba M, Masiga DK, Sang R, Villinger J. Has Rift Valley fever virus evolved with increasing severity in human populations in East Africa?. Emerg Microbes Infect 2016;5:e581–10 [CrossRef]
    [Google Scholar]
  38. FAO EMPRES Transboundary animal diseases Bulletin FAO corporate document Repository 2000; pp4–9
    [Google Scholar]
  39. Peyre M, Chevalier V, Abdo-Salem S, Velthuis A, Antoine-Moussiaux N et al. A systematic scoping study of the socio-economic impact of Rift Valley fever: research gaps and needs. Zoonoses Public Health 2015;62:309–325 [CrossRef]
    [Google Scholar]
  40. Orinde AB, Kimani T, Schelling E, Omolo J, Kikuvi GM et al. Estimation of the Rift Valley Fever Burden of Disease in the 2006/2007 Outbreak in Kenya ILRI, Nairobi: 61st Conference of the American society of Tropical Medicine and Hygiene; 2012
    [Google Scholar]
  41. Baba S, Eric T, Dirk B, Ahmed HA, Guido VH. Effects of livestock importbans imposed by Saudi Arabia on Somaliland for sanitary reasons related to Rift Valley fever. Outlook on AGRICULTURE 2006;35:19–24
    [Google Scholar]
  42. Clark MHA, Warimwe GM, Di Nardo A, Lyons NA, Gubbins S. Systematic literature review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in Africa from 1968 to 2016. PLoS Negl Trop Dis 2018;12:e0006627-ee0006627 [CrossRef]
    [Google Scholar]
  43. LaBeaud AD, Pfeil S, Muiruri S, Dahir S, Sutherland LJ et al. Factors associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya. PLoS Negl Trop Dis 2015;9:e0003548 [CrossRef]
    [Google Scholar]
  44. Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P et al. An outbreak of Rift Valley fever in northeastern Kenya, 1997-98. Emerg Infect Dis 2002;8:138–144 [CrossRef]
    [Google Scholar]
  45. Grossi-Soyster EN, Banda T, Teng CY, Muchiri EM, Mungai PL et al. Rift Valley fever seroprevalence in Coastal Kenya. Am J Trop Med Hyg 2017;97:115–120 [CrossRef]
    [Google Scholar]
  46. CDC 2018; Rift Valley fever (RVF) centers for disease control and prevention. https://wwwnc.cdc.gov/travel/diseases/rift-river-valley
  47. Meegan JM, Khalil GM, Hoogstraal H, Adham FK. Experimental transmission and field isolation studies implicating Culex pipiens as a vector of Rift Valley fever virus in Egypt. Am J Trop Med Hyg 1980;29:1405–1410 [CrossRef]
    [Google Scholar]
  48. Liu J, Sun Y, Shi W, Tan S, Pan Y et al. The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. Emerg Microbes Infect 2017;6:e4 [CrossRef]
    [Google Scholar]
  49. Mohamed M, Mosha F, Mghamba J, Zaki SR, Shieh WJ et al. Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. Am J Trop Med Hyg 2010;83:22–27 [CrossRef]
    [Google Scholar]
  50. Hise AG, Traylor Z, Hall NB, Sutherland LJ, Dahir S et al. Association of symptoms and severity of Rift Valley fever with genetic polymorphisms in human innate immune pathways. PLoS Negl Trop Dis 2015;9:e0003584 [CrossRef]
    [Google Scholar]
  51. Lichoti JK, Kihara A, Oriko AA, Okutoyi LA, Wauna JO et al. Detection of Rift Valley fever virus interepidemic activity in some hotspot areas of Kenya by sentinel animal surveillance, 2009–2012. Vet Med Int 2014;2014:1–9 [CrossRef]
    [Google Scholar]
  52. Lernout T, Cardinale E, Jego M, Desprès P, Collet L et al. Rift Valley fever in humans and animals in Mayotte, an endemic situation?. PLoS One 2013;8:e74192 [CrossRef]
    [Google Scholar]
  53. Smithburn KC, Mahaffy AF, Haddow AJ, Kitchen SF, Smith JF. Rift Valley fever; accidental infections among laboratory workers. Journal of immunology 1949;62:213–227
    [Google Scholar]
  54. Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses 2011;3:493–519 [CrossRef]
    [Google Scholar]
  55. Nguku PM, Sang R, Amwayi S, Sharif SK, Hightower A et al. An investigation of a major outbreak of Rift Valley fever in Kenya: 2006–2007. Am J Trop Med Hyg 2010;83:05–13 [CrossRef]
    [Google Scholar]
  56. McElroy AK, Nichol ST. Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 2012;422:6–12 [CrossRef]
    [Google Scholar]
  57. Meegan JM, Watten RH, Laughlin LW. Clinical experience with Rift Valley fever in humans during the 1977 Egyptian epizootic. Contrib Epidemiol Biostat 1981;3:114–123
    [Google Scholar]
  58. Arthur RR, el-Sharkawy MS, Cope SE, Botros BA, Oun S et al. Recurrence of Rift Valley fever in Egypt. Lancet 1993;342:1149–1150 [CrossRef]
    [Google Scholar]
  59. Al-Hazmi A, Al-Rajhi AA, Abboud EB, Ayoola EA, Al-Hazmi M et al. Ocular complications of Rift Valley fever outbreak in Saudi Arabia. Ophthalmology 2005;112:313–318 [CrossRef]
    [Google Scholar]
  60. Freed I. Rift Valley fever in man, complicated by retinal changes and loss of vision. S Afr Med J 1951;25:930–932
    [Google Scholar]
  61. Abdel-Aziz AA, Meegan JM, Laughlin LW. Rift Valley fever as a possible cause of human abortions. Trans R Soc Trop Med Hyg 1980;74:685–686 [CrossRef]
    [Google Scholar]
  62. Baudin M, Jumaa AM, Jomma HJE, Karsany MS, Bucht G et al. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study. Lancet Glob Health 2016;4:e864–e871 [CrossRef]
    [Google Scholar]
  63. Swartz TA, Klinberg MA, Goldblum N, C.M. P. (editors) The symptomatology and pathology of Rift Valley fever in domestic animals 1981
    [Google Scholar]
  64. Hartman A, Fever RV. Rift Valley fever. Clin Lab Med 2017;37:285–301 [CrossRef]
    [Google Scholar]
  65. Faburay B, Gaudreault NN, Liu Q, Davis AS, Shivanna V et al. Development of a sheep challenge model for Rift Valley fever. Virology 2016;489:128–140 [CrossRef]
    [Google Scholar]
  66. Wilson W, Davis A, Gaudreault N, Faburay B, Trujillo J et al. Experimental infection of calves by two genetically-distinct strains of Rift Valley fever virus. Viruses 2016;8:145 [CrossRef]
    [Google Scholar]
  67. El Mamy AB, Baba MO, Barry Y, Isselmou K, Dia ML et al. Unexpected Rift Valley fever outbreak, Northern Mauritania. Emerg Infect Dis 2011;17:1894–1896
    [Google Scholar]
  68. Weingartl HM, Zhang S, Marszal P, McGreevy A, Burton L et al. Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells. PLoS One 2014;9:e87385 [CrossRef]
    [Google Scholar]
  69. Kreher F, Tamietti C, Gommet C, Guillemot L, Ermonval M et al. The Rift Valley fever accessory proteins NSm and P78/NSm-GN are distinct determinants of virus propagation in vertebrate and invertebrate hosts. Emerg Microbes Infect 2014;3:1–12 [CrossRef]
    [Google Scholar]
  70. Halldorsson S, Li S, Li M, Harlos K, Bowden TA et al. Shielding and activation of a viral membrane fusion protein. Nat Commun 2018;9:349 [CrossRef]
    [Google Scholar]
  71. Freiberg AN, Sherman MB, Morais MC, Holbrook MR, Watowich SJ. Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography. J Virol 2008;82:10341–10348 [CrossRef]
    [Google Scholar]
  72. Sherman MB, Freiberg AN, Holbrook MR, Watowich SJ. Single-particle cryo-electron microscopy of Rift Valley fever virus. Virology 2009;387:11–15 [CrossRef]
    [Google Scholar]
  73. Huiskonen JT, Overby AK, Weber F, Grünewald K. Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: evidence for GN-GC glycoprotein heterodimers. J Virol 2009;83:3762–3769 [CrossRef]
    [Google Scholar]
  74. Halldorsson S, Behrens AJ, Harlos K, Huiskonen JT, Elliott RM et al. Structure of a phleboviral envelope glycoprotein reveals a consolidated model of membrane fusion. Proc Natl Acad Sci U S A 2016;113:7154–7159 [CrossRef]
    [Google Scholar]
  75. de Boer SM, Kortekaas J, Spel L, Rottier PJM, Moormann RJM et al. Acid-activated structural reorganization of the Rift Valley fever virus GC fusion protein. J Virol 2012;86:13642–13652 [CrossRef]
    [Google Scholar]
  76. Harmon B, Schudel BR, Maar D, Kozina C, Ikegami T et al. Rift Valley fever virus strain MP-12 enters mammalian host cells via caveola-mediated endocytosis. J Virol 2012;86:12954–12970 [CrossRef]
    [Google Scholar]
  77. Guardado-Calvo P, Bignon EA, Stettner E, Jeffers SA, Pérez-Vargas J et al. Mechanistic insight into Bunyavirus-Induced membrane fusion from structure-function analyses of The Hantavirus envelope glycoprotein gC. PLoS Pathog 2016;12:e1005813 [CrossRef]
    [Google Scholar]
  78. Willensky S, Bar-Rogovsky H, Bignon EA, Tischler ND, Modis Y et al. Crystal structure of glycoprotein C from a hantavirus in the Post-fusion conformation. PLoS Pathog 2016;12:e1005948 [CrossRef]
    [Google Scholar]
  79. Zhu Y, Wu Y, Chai Y, Qi J, Peng R et al. The postfusion structure of the heartland virus GC glycoprotein supports taxonomic separation of the Bunyaviral families Phenuiviridae and Hantaviridae. Journal of virology 2018;92:
    [Google Scholar]
  80. Wu Y, Zhu Y, Gao F, Jiao Y, Oladejo BO et al. Structures of phlebovirus glycoprotein GN and identification of a neutralizing antibody epitope. Proc Natl Acad Sci U S A 2017;114:E7564–E7573 [CrossRef]
    [Google Scholar]
  81. Lozach P-Y, Kühbacher A, Meier R, Mancini R, Bitto D et al. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 2011;10:75–88 [CrossRef]
    [Google Scholar]
  82. Phoenix I, Nishiyama S, Lokugamage N, Hill TE, Huante MB et al. N-glycans on the Rift Valley fever virus envelope glycoproteins GN and GC redundantly support viral infection via DC-SIGN. Viruses 2016;8:149 [CrossRef]
    [Google Scholar]
  83. Léger P, Tetard M, Youness B, Cordes N, Rouxel RN et al. Differential use of the C-type lectins L-SIGN and DC-SIGN for phlebovirus endocytosis. Traffic 2016;17:639–656 [CrossRef]
    [Google Scholar]
  84. Lozach P-Y, Kühbacher A, Meier R, Mancini R, Bitto D et al. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 2011;10:75–88 [CrossRef]
    [Google Scholar]
  85. Riblett AM, Blomen VA, Jae LT, Altamura LA, Doms RW et al. A haploid genetic screen identifies heparan sulfate proteoglycans supporting Rift Valley fever virus infection. J Virol 2016;90:1414–1423 [CrossRef]
    [Google Scholar]
  86. de Boer SM, Kortekaas J, de Haan CAM, Rottier PJM, Moormann RJM et al. Heparan sulfate facilitates Rift Valley fever virus entry into the cell. J Virol 2012;86:13767–13771 [CrossRef]
    [Google Scholar]
  87. Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA et al. (editors) Fields Virology, 6 ed. Lippincot Williams & Wilkins; 2013
    [Google Scholar]
  88. Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT et al. Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis 2011;17:2270–2276 [CrossRef]
    [Google Scholar]
  89. Bird BH, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST. Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J Virol 2007;81:2805–2816 [CrossRef]
    [Google Scholar]
  90. Battles JK, Dalrymple JM. Genetic variation among geographic isolates of Rift Valley fever virus. Am J Trop Med Hyg 1988;39:617–631 [CrossRef]
    [Google Scholar]
  91. Nanyingi MO, Munyua P, Kiama SG, Muchemi GM, Thumbi SM et al. A systematic review of Rift Valley fever epidemiology 1931-2014. Infect Ecol Epidemiol 2015;5:28024 [CrossRef]
    [Google Scholar]
  92. FAO The last hurdles towards Rift Valley Fever control Report on the Ad hoc workshop on the Current State of Rift Valley Fever Vaccine And Diagnostics Development9 Rome, Italy: FAO Animal Production and Health Report, No; 2015
    [Google Scholar]
  93. Allen ER, Krumm SA, Raghwani J, Halldorsson S, Elliott A et al. A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus. Cell Rep 2018;25:3750–3758 [CrossRef]
    [Google Scholar]
  94. Eddy GA, Peters CJ, Meadors G, Cole FE Jr. Rift valley fever vaccine for humans In Swartz TA, Klinberg MA, Goldblum N, Papier CM. (editors) Contributions to epidemiology and biostatistics S. Karger AG, Basel: Rift Valley fever; 1981; pp124–141
    [Google Scholar]
  95. Peters CJ, Jones D, Trotter R, Donaldson J, White J et al. Experimental Rift Valley fever in rhesus macaques. Arch Virol 1988;99:31–44 [CrossRef]
    [Google Scholar]
  96. Labeaud D. Towards a safe, effective vaccine for Rift Valley fever virus. Future Virol 2010;5:675–678 [CrossRef]
    [Google Scholar]
  97. Brown RD, Scott GR, Dalling T. Persistence of antibodies to Rift Valley fever in man. The Lancet 1957;270:345 [CrossRef]
    [Google Scholar]
  98. McElroy AK, Albariño CG, Nichol ST. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol J 2009;6:125 [CrossRef]
    [Google Scholar]
  99. Fafetine JM, Tijhaar E, Paweska JT, Neves LCBG, Hendriks J et al. Cloning and expression of Rift Valley fever virus nucleocapsid (N) protein and evaluation of a N-protein based indirect ELISA for the detection of specific IgG and IgM antibodies in domestic ruminants. Vet Microbiol 2007;121:29–38 [CrossRef]
    [Google Scholar]
  100. Besselaar TG, Blackburn NK. Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies. Arch Virol 1991;121:111–124 [CrossRef]
    [Google Scholar]
  101. Besselaar TG, Blackburn NK. The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins. Arch Virol 1992;125:239–250 [CrossRef]
    [Google Scholar]
  102. Lagerqvist N, Näslund J, Lundkvist A, Bouloy M, Ahlm C et al. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley fever virus cDNA constructs. Virol J 2009;6:6 [CrossRef]
    [Google Scholar]
  103. Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR et al. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006;24:7181–7189 [CrossRef]
    [Google Scholar]
  104. Warimwe GM, Gesharisha J, Carr BV, Otieno S, Otingah K et al. Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever. Sci Rep 2016;6:20617 [CrossRef]
    [Google Scholar]
  105. López-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M et al. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl Trop Dis 2013;7:e2309 [CrossRef]
    [Google Scholar]
  106. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446–448 [CrossRef]
    [Google Scholar]
  107. Wang F, Ekiert DC, Ahmad I, Yu W, Zhang Y et al. Reshaping antibody diversity. Cell 2013;153:1379–1393 [CrossRef]
    [Google Scholar]
  108. Oscherwitz J. The promise and challenge of epitope-focused vaccines. Hum Vaccin Immunother 2016;12:2113–2116 [CrossRef]
    [Google Scholar]
  109. Terasaki K, Makino S. Interplay between the virus and host in Rift Valley fever pathogenesis. J Innate Immun 2015;7:450–458 [CrossRef]
    [Google Scholar]
  110. Wonderlich ER, Caroline AL, McMillen CM, Walters AW, Reed DS et al. Peripheral blood biomarkers of disease outcome in a monkey model of Rift Valley fever encephalitis. J Virol 2018;92:e01662–17 [CrossRef]
    [Google Scholar]
  111. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF et al. Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep. Vaccine 2010;28:4581–4587 [CrossRef]
    [Google Scholar]
  112. von Teichman B, Engelbrecht A, Zulu G, Dungu B, Pardini A et al. Safety and efficacy of Rift Valley fever Smithburn and clone 13 vaccines in calves. Vaccine 2011;29:5771–5777 [CrossRef]
    [Google Scholar]
  113. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J et al. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSS. J Virol 2001;75:1371–1377 [CrossRef]
    [Google Scholar]
  114. Njenga MK, Njagi L, Thumbi SM, Kahariri S, Githinji J et al. Randomized controlled field trial to assess the immunogenicity and safety of Rift Valley fever clone 13 vaccine in livestock. PLoS Negl Trop Dis 2015;9:e0003550 [CrossRef]
    [Google Scholar]
  115. Ly HJ, Ikegami T. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSS proteins. Virol J 2016;13:118 [CrossRef]
    [Google Scholar]
  116. Le May N, Mansuroglu Z, Léger P, Josse T, Blot G et al. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 2008;4:e13 [CrossRef]
    [Google Scholar]
  117. Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M et al. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 2004;116:541–550 [CrossRef]
    [Google Scholar]
  118. Swanepoel R, Blackburn NK. Demonstration of nuclear immunofluorescence in Rift Valley fever infected cells. J Gen Virol 1977;34:557–561 [CrossRef]
    [Google Scholar]
  119. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ et al. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 2009;5:e1000287 [CrossRef]
    [Google Scholar]
  120. Ikegami T. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Rev Vaccines 2017;16:601–611 [CrossRef]
    [Google Scholar]
  121. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999;18:181–189 [CrossRef]
    [Google Scholar]
  122. von Teichman B, Engelbrecht A, Zulu G, Dungu B, Pardini A et al. Safety and efficacy of Rift Valley fever Smithburn and clone 13 vaccines in calves. Vaccine 2011;29:5771–5777 [CrossRef]
    [Google Scholar]
  123. Wilson WC, Bawa B, Drolet BS, Lehiy C, Faburay B et al. Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination. Vet Microbiol 2014;172:44–50 [CrossRef]
    [Google Scholar]
  124. Mroz C, Gwida M, El-Ashker M, Ziegler U, Homeier-Bachmann T et al. Rift Valley fever virus infections in Egyptian cattle and their prevention. Transbound Emerg Dis 2017;64:2049–2058 [CrossRef]
    [Google Scholar]
  125. Zidan S, Byomi A, Samaha H, Hadad G. Some associated risk factors with occurrence of Rift Valley fever in some animals and man in certain localities of Nile Delta, Egypt. 2015
  126. Dungu B, Donadeu M, Bouloy M. Vaccination for the control of Rift Valley fever in enzootic and epizootic situations. Dev Biol 2013;135:61–72 [CrossRef]
    [Google Scholar]
  127. Jansen van Vuren P, Tiemessen CT, Paweska JT. Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS One 2011;6:e25027 [CrossRef]
    [Google Scholar]
  128. Xu W, Watts DM, Costanzo MC, Tang X, Venegas LA et al. The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PLoS One 2013;8:e59210 [CrossRef]
    [Google Scholar]
  129. Wang Q, Ma T, Wu Y, Chen Z, Zeng H et al. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nat Microbiol 2019;34: [CrossRef]
    [Google Scholar]
  130. Keegan K, Collett MS. Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J Virol 1986;58:263–270
    [Google Scholar]
  131. Williams R, Ellis CE, Smith SJ, Potgieter CA, Wallace D et al. Validation of an IgM antibody capture ELISA based on a recombinant nucleoprotein for identification of domestic ruminants infected with Rift Valley fever virus. J Virol Methods 2011;177:140–146 [CrossRef]
    [Google Scholar]
  132. Atkins C, Freiberg AN. Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection. Future Virol 2017;12:651–665 [CrossRef]
    [Google Scholar]
  133. Faburay B, LaBeaud AD, McVey DS, Wilson WC, Richt JA. Current status of Rift Valley fever vaccine development. Vaccines 2017;5:E29 [CrossRef]
    [Google Scholar]
  134. Dungu B, Lubisi BA, Ikegami T. Rift Valley fever vaccines: current and future needs. Curr Opin Virol 2018;29:8–15 [CrossRef]
    [Google Scholar]
  135. Ikegami T, Hill TE, Smith JK, Zhang L, Juelich TL et al. Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial Attenuations in the S, M, and L segments. J Virol 2015;89:7262–7276 [CrossRef]
    [Google Scholar]
  136. Botros B, Omar A, Elian K, Mohamed G, Soliman A et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 2006;78:787–791 [CrossRef]
    [Google Scholar]
  137. Ahmed Kamal S. Observations on Rift Valley fever virus and vaccines in Egypt. Virol J 2011;8:532 [CrossRef]
    [Google Scholar]
  138. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995;53:405–411 [CrossRef]
    [Google Scholar]
  139. Makoschey B, van Kilsdonk E, Hubers WR, Vrijenhoek MP, Smit M et al. Rift Valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths. PLoS Negl Trop Dis 2016;10:e0004550 [CrossRef]
    [Google Scholar]
  140. Faburay B, Wilson WC, Gaudreault NN, Davis AS, Shivanna V et al. A recombinant Rift Valley fever virus glycoprotein subunit vaccine confers full protection against Rift Valley fever challenge in sheep. Sci Rep 2016;6:27719 [CrossRef]
    [Google Scholar]
  141. Wichgers Schreur PJ, Kant J, van Keulen L, Moormann RJM, Kortekaas J. Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination. Vaccine 2015;33:1459–1464 [CrossRef]
    [Google Scholar]
  142. Wichgers Schreur PJ, van Keulen L, Kant J, Kortekaas J. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy. Vaccine 2017;35:3123–3128 [CrossRef]
    [Google Scholar]
  143. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther 2014;22:668–674 [CrossRef]
    [Google Scholar]
  144. Stylianou E, Griffiths KL, Poyntz HC, Harrington-Kandt R, Dicks MD et al. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine 2015;33:6800–6808 [CrossRef]
    [Google Scholar]
  145. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004;10:S110–S121 [CrossRef]
    [Google Scholar]
  146. Sands P, Mundaca-Shah C, Dzau VJ. The neglected dimension of global security-A framework for countering infectious-disease crises. N Engl J Med 2016;374:1281–1287 [CrossRef]
    [Google Scholar]
  147. Bird BH, Nichol ST. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol 2012;2:315–323 [CrossRef]
    [Google Scholar]
  148. Davies FG. The historical and recent impact of Rift Valley fever in Africa. Am J Trop Med Hyg 2010;83:73–74 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001296
Loading
/content/journal/jgv/10.1099/jgv.0.001296
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error